The Lausanne-based team of US investment firm, +ND Capital, today marked its second successful exit in the European biotechnology market as Belgian biotech company, Galapagos NV (Euronext & NASDAQ: GLPG), announced1 that it will acquire Dutch cell therapy company CellPoint. +ND Capital was the sole venture investor in CellPoint, a company dedicated to developing CAR-T therapies at the point-of-care.
June 21, 2022
· 5 min read